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Abstract
Background: The evaluation of solitary pulmonary lesions (SPL) requires a balance between procedure-related
morbidity and diagnostic yield, particularly in areas where tuberculosis (TB) is endemic. Data on ultrathin bronchoscopy
(UB) for this purpose is limited. To evaluate feasibility and safety of UB compared to SB for diagnosis of SPL in a TB
endemic region.
Methods: In this prospective randomised trial we compared diagnostic yield and adverse events of UB with standard-
size bronchoscopy (SB), both combined with fluoroscopy, in a cohort of patients with SPL located beyond the visible
range of SB.
Results: We included 40 patients (mean age 55.2 years, 45 % male) with malignant SPL (n = 16; 40 %), tuberculous
SPL (n = 11; 27.5 %) and other benign SPL (n = 13; 32.5 %). Mean procedure time in UB and SB was 30.6 and 26.0 min,
respectively (p = 0.15). By trend, adverse events were recorded more often with UB than with SB (30.0 vs.
5.0 %, p = 0.091), including extensive coughing (n = 2), blocked working channel (n = 2), and arterial hypertension
requiring therapeutic intervention (n = 1), all with UB. The overall diagnostic yield of UB compared to SB was 55.0 %
vs. 80.0 %, respectively (p = 0.18). Sensitivity for the diagnosis of malignancy of UB and SB was 50.0 % and 62.5 %,
respectively (p = 0.95).
Conclusion: UB is not superior to SB for the evaluation of SPL in a region endemic with tuberculosis, when combined
with fluoroscopic guidance only.
Trial registration: ClinicalTrials.gov (Identifier: NCT02490059).
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Background
Solitary pulmonary lesions (SPL) are frequently detected
in computed tomography (CT) scans of the chest. A
fourth of the patients who underwent a low-dose chest
CT scan in the U.S. National Lung Screening Trial
(NSLT) had a positive screening result; mostly present-
ing as one or more SPL or a pulmonary mass suspicious
for lung cancer [1]. Thus, by following a lung cancer
screening program with low-dose chest CT, an increas-
ing number of SPL for evaluation is to be expected.
However, more than 95 % of SPL detected by low-dose
CT screening show false positive findings due to a non-
malignant final diagnosis [1]. In a tuberculosis (TB) en-
demic area, the prevalence of benign SPL may be even
higher [2], and therefore efforts have been undertaken to
establish diagnostic modalities to distinguish between
malignant and benign lesions without excess periopera-
tive mortality [3]. According to guidelines for the diag-
nosis of SPL, there are three possibilities to manage
these patients depending on the probability of an under-
lying malignancy: serial CT scans, tissue biopsy, or direct
surgical resection [4]. Direct surgical resection is not
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justified in the majority of cases given the high rate of
false positive findings in the context of SPL in a high TB
burden environment. The goal is to diagnose malignant
SPL promptly, to permit timely surgical resection, while
avoiding invasive testing or surgery in patients with be-
nign SPL [5]. The sensitivity of traditional transbronchial
biopsy (TBB) with flexible bronchoscopy ranges between
14 % and 63 %, depending on size and location of the
SPL [6]. Recently, new navigational bronchoscopy tech-
niques have emerged which guide the bronchoscopist to
the SPL using various image-processing modalities.
These technologies including electromagnetic navigation
bronchoscopy (ENB), virtual bronchoscopy (VB), and ra-
dial endobronchial ultrasound (R-EBUS) have shown to
have a better diagnostic yield than traditional TBB [5].
In countries with limited resources, these technologies
may not be available due to financial constraints.
Data on the utility of ultrathin bronchoscopy (UB) for the
diagnosis of SPL is limited [7]. The smaller outer diameter
of the instrument might improve access to SPL not visible
by standard-size bronchoscopy (SB) and thus improve the
diagnostic yield compared to TBB using SB. Based on the
considerably smaller outer diameter of the UB it may be
possible to visualise endoscopically more peripheral lesions
and thus increase the yield of sampling in the area of inter-
est. We undertook this prospective randomised trial to
compare the overall diagnostic yield and adverse event rate
of UB with that of SB for the diagnosis of SPL in lesions
that were not visible on SB in a TB endemic region.
Methods
Study design and patient selection
The present prospective single-centre randomised pilot
study was performed at Tygerberg Academic Hospital, a
tertiary university hospital in Cape Town, South Africa,
with a referral drainage area of 1.5 million people and
TB notification rate of up to 1’000/100’000 persons per
year when the study was performed. Between November
2000 and November 2003 all patients referred to the
lung unit with single pulmonary lesion ≤ 6 cm in diam-
eter on chest CT were considered. SPL was defined as a
single and circumscribed pulmonary lesion with a diam-
eter ≤ 6.0 cm, surrounded by aerated lung tissue, without
evidence of satellite lesions, adenopathy or characteristic
signs of malignant or benign lesions [3]. Location and
maximal diameter of all indeterminate SPLs were re-
corded from the chest CT prior to enrolment of pa-
tients. Inclusion criteria were a previous cytological and
microbiological negative sputum examination, absence
of enlarged mediastinal or hilar lymph nodes on chest
CT scan, and informed consent obtained before start of
the procedure. Exclusion criteria were SPL with lesion
size unchanged over two years, inability to undergo
bronchoscopy or thoracotomy, and pregnancy. The
study flow diagram is displayed in Fig. 1. Participants
with consent for participation in the study in whom the
lesion was found to be visible on SB were then not
randomised and not considered part of the study popu-
lation. Written informed consent was obtained from all
patients before inclusion in the study, which was ap-
proved by the Committee for Human Research of
Stellenbosch University (Cape Town, South Africa) with
the reference number 2000/C094. The study is registered
at ClinicalTrials.gov (Identifier: NCT02490059).
Randomisation during bronchoscopic procedure
All procedures were started using SB with an external
diameter of 5.0–6.0 mm with a biopsy channel of 2.2–
Fig. 1 Study flow diagram (CONSORT flow chart)
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2.8 mm (models Olympus BF-30 and BF-1 T160, Olym-
pus, Tokyo, Japan). If during SB the lesion was endo-
scopically visible the bronchoscopy was continued as
standard diagnostic procedure and the patients were ex-
cluded from the analysis. Only if no tumour was visible
during complete inspection of the bronchial tree using
the SB, a participant was randomised by opening a num-
bered sealed opaque envelope. Randomisation was per-
formed using sequentially numbered (1–40) sealed
opaque envelopes (block randomisation: block size 4).
For subjects allocated to the SB group, the examination
was immediately continued with the same SB broncho-
scope. For subjects randomised to UB, the instrument
was changed immediately to an Olympus BF-XP 40
ultrathin bronchoscope with an outer diameter of
2.8 mm and a working channel 1.2 mm during the same
bronchoscopy session.
Procedural details
Five experienced operators performed all procedures
under topical anaesthesia (1 % lidocaine) and conscious
sedation (intravenous midazolam). Sampling of SPL was
performed with brush and forceps biopsies under fluoro-
scopic guidance, and with bronchial washing as deemed
appropriate by the bronchoscopist. Using all modalities
was encouraged by the protocol. Three or more samples
were taken using the biopsy forceps and at least 2 sam-
ples using the brush. A study-specific case report form
including a checklist on the bronchoscopic procedures
and findings was completed by the bronchoscopist dir-
ectly after the procedure. The lesion was considered
“reached” if the biopsy forceps and/or brush were placed
within the lesion, and it was considered “moved” when
push and pull manoeuvers with the biopsy forceps and/
or brush were transferrable to the lesion, both as
assessed by two-dimensional fluoroscopic visualisation.
Procedure duration time was measured from insertion
of bronchoscope to extraction and in the case of ran-
domisation to UB included the change over time from
SB to UB. All laboratory staff was blinded to study group
allocation. Biopsy specimens obtained by bronchoscopy
were compared with the diagnosis made by surgical re-
section or CT-guided trans-thoracic needle aspiration if
applicable. Efforts were made to obtain confirmatory
histological diagnosis for all patients. Alternatively, when
invasive diagnosis was not feasible or appropriate (as
assessed by a multidisciplinary tumour board) radio-
logical follow-up examinations were performed over two
years.
Outcomes
The primary outcome was to determine and compare
the overall diagnostic yield and the sensitivity for the
diagnosis of malignancy of UB versus SB. The diagnostic
yield was calculated by identifying cases for which a de-
finitive histological or cytological diagnosis could be
made or follow-up examinations after two years sug-
gested a benign disease. The following formula was used
to compute the overall diagnostic yield: diagnostic yield
(%) = 100 × cases diagnosed by UB or SB/total number of
patients with completed procedures. The sensitivity was
calculated as previously described [8], and is related to
the diagnosis of malignancy. The secondary outcome
was to compare the adverse event rate and procedure
duration of UB versus SB.
Adverse events
The intensity levels of the adverse events (AEs) were
graded according to a standard three-grade scale [9].
Grade 1, or mild AE, was defined as “no effect on bron-
choscopic procedure”; Grade 2, or moderate AE, was
considered when “some interference with bronchoscopic
procedure” occurred; and Grade 3, or severe AE, was
present if “early termination of bronchoscopy was re-
quired”. For purpose of this study only grade 2 and 3
AEs were recorded.
Statistical analysis
All statistical analyses were performed using IBM SPSS
Statistics for Windows, version 22 (IBM corporation,
Armonk NY, USA). Data are reported as median (inter-
quartile range, IQR), or mean ± standard deviation (SD),
or percentages as appropriate. Distribution of normality
was tested with the one-sample Kolmogorov-Smirnov
test. The difference between patients between the groups
was calculated using the Fisher’s exact test (for 2 × 2
tables) or χ2 test for categorical data, and Mann–
Whitney U-test or student’s t-test for continuous data.
Both overall diagnostic yield and sensitivity between
the groups were compared using the χ2 test. P-values
of all outcomes were two-sided; a value less than 0.05
was considered to indicate statistical significance.
There was no sample size calculation as the study
was designed as a pilot trial to test feasibility.
Results
Forty patients were included in the study (see Additional
file 1). Baseline characteristics and the final diagnoses
are displayed in Table 1. Neither localization of SPL in the
upper lobes (p = 0.33), nor lesion size > 3 cm was associ-
ated with active TB (p = 0.21). Although none of the lesions
were visible by SB (inclusion criterion), two of the 20 le-
sions (10 %) were visualized endoscopically by UB. The
mean procedure time for UB and SB allocated patients was
30.6 and 26.0 min, respectively (p = 0.15). By trend, AEs
were significantly more frequent in the UB compared to
the SB group (30.0 vs. 5.0 %, p = 0.091). AEs in the UB
group included extensive coughing (n = 2), blocked
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working channel or weak suctioning (n = 3), and
hypertensive urgency requiring therapeutic interven-
tion (n = 1). No grade 3 AEs were documented. In the
SB group, there was one case of extensive bleeding,
which was stopped by topical application of adren-
aline through the working channel of the broncho-
scope. Procedural details were equally distributed
within the groups (Table 2). The overall diagnostic
yield of fluoroscopic guided UB compared to SB was
55.0 % vs. 80.0 %, respectively (p = 0.18). Sensitivity
for the diagnosis of malignancy of UB and SB was
50.0 % and 62.5 %, respectively (Table 3). Rates of
true positives, true negatives and false negatives in
UB compared to SB were 20 % vs. 25 %, 60 % vs.
60 %, and 20 % vs. 15 %, respectively. The diagnostic
yield of lesions that were fluoroscopically moved was
90.9 % compared to 88.0 % in lesions that were fluo-
roscopically reached. However, only a “reached” SPL
was a significant predictor of the diagnostic yield (p <
0.001), whereas a “moveable” SPL was not significant
(p = 0.052). The size of the lesion was not significantly
associated with increased diagnostic yield (p = 0.40).
Discussion
This randomised trial investigating endoscopically nonvi-
sible SPL up to 6 cm diameter by SB showed no diagnostic
benefit of switching to UB for the diagnostic broncho-
scopic sampling when compared to the procedure
Table 1 Baseline characteristics of patients in the study
Ultrathin bronchoscopy
(n = 20)
Standard size bronchoscopy
(n = 20)
P value
Age, mean (SD), y 54.8 (12.4) 55.7 (12.7) 0.72
Male gender, No. (%) 10 (50.0) 8 (40.0) 0.75
Previous tuberculosis, No. (%) 4 (20.0) 4 (20.0) 0.99
Lobar localisation 0.65
Upper lobe, No. (%) 12 (60.0) 11 (55.0)
Middle lobe, No. (%) 2 (10.0) 1 (5.0)
Lower lobe, No. (%) 6 (30.0) 8 (40.0)
Lesion size, median (IQR), cm 2.7 (1.7–3.5) 2.4 (1.8–3.9) 0.40
Lesion size≥ 2 cm, No. (%) 14 (70.0) 14 (70.0) 0.99
NSCLC, No. (%) 8 (40.0) 8 (40.0)
Benign final diagnosis, No. (%) 12 (60.0) 12 (60.0) 0.66
Tuberculosis 5 (25.0) 6 (30.0)
Otherwise benign lesiona 7 (35.0) 6 (30.0)
Confirmation of final diagnosis 0.62
Surgery 11 (55.0) 8 (40.0)
Radiological follow-up (no histological confirmation) 8 (40.0) 11 (55.0)
Loss of follow-up (no histological confirmation) 1 (5.0) 1 (5.0)
ascar (n = 1), bacterial infection (n = 2), silicosis (n = 1), hamartoma (n = 1), unknown (n = 8)
SD standard deviation, IQR interquartile range, NSCLC non-small cell lung cancer
Table 2 Procedural details
Ultrathin bronchoscopy
(n = 20)
Standard size bronchoscopy
(n = 20)
P value
Biopsy method, No. (%)
Forceps 14 (70.0) 10 (50.0) 0.33
Brushing 14 (70.0) 18 (90.0) 0.23
Washing 20 (100) 19 (95.0) 0.99
Combination of all three methods 12 (60.0) 7 (35.0) 1
Combination of two methods 4 (20.0) 12 (60.0) 0.99
Washing only 4 (20.0) 1 (5.0) 1
Lesion reached, No. (%)a 12 (60.0) 13 (65.0) 0.99
Lesion moved, No. (%)a 4 (20.0) 7 (35.0) 0.48
afluoroscopically determined
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performed with the SB alone, when used under fluoro-
scopic guidance. There is only limited evidence from ran-
domised controlled trials comparing the diagnostic yield
of UB with that of SB. We found that UB had no diagnos-
tic advantage compared to SB but was more cumbersome
for operators. Moreover, the procedure time was nearly
five minutes longer with UB, although the difference was
not statistically significant. The clinical relevance of four
minutes time difference can maybe neglected, since the
change from the standard to the ultrathin bronchoscope is
omitted in daily routine but was part of procedure
time here. Although the classical definition of SPLs
considers lesions ≤ 3 cm, we have chosen to investi-
gate lesions ≤ 6 cm, since tuberculomas of nearly
double that size have been reported [10].
Data concerning the diagnostic yield of fluoroscopic
guided UB compared to SB in the literature is scarce,
especially for the evaluation of SPL. Considering the
existing evidence in this field, the diagnostic yield of
fluoroscopic guided UB in our study (55.0 %) was within
the published range from 30.0 to 69.0 % reported by
others [11–13], although these studies used different
sampling methods and were in different populations. In
a small prospective, single-arm study published by
Rooney et al. on 17 patients, the diagnostic yield of UB
was only 30.0 %, perhaps because only a small biopsy
brush was used for the ultrathin bronchoscope [11]. The
combined use of histological and cytological biopsy tech-
niques has led to an improved diagnostic yield obtained
with UB of 60.0 % [12]. Using a slightly thicker broncho-
scope (outer diameter 3.5 mm) in a prospective study on
102 patients, Oki et al. reported a diagnostic yield of
69.0 % for the thin bronchoscopy irrespective of lesion
size. This result was obtained without using a brush;
only forceps biopsy and bronchial washing were per-
formed [13]. We used forceps, brushing, and bronchial
washings under fluoroscopic guidance as sampling
methods. We did not investigate the diagnostic utility of
the combined use of UB and SB in this context as sam-
pling was only performed with the allocated broncho-
scope (UB or SB). The diagnostic yield in our study may
have been influenced by the prevalence of TB in our co-
hort (27.5 %), which is clearly higher than in the three
other studies ranging from 5.9 to 12.5 %.
Technological advances in recent years have led to the
availability of newer modalities helping to navigate to
SPLs [14]. The weighted diagnostic yield of ENB, VB,
and R-EBUS for the work-up of SPLs without the use of
UB is in the range of 67–74 % which is comparable with
conventional methods mentioned above [5, 15]. How-
ever, in the context of the new navigational broncho-
scopic techniques the utility of UB needs to be
reinvestigated. The usefulness of UB may play an im-
portant role when it is used with other new modalities
such as CT-fluoroscopy or virtual bronchoscopic naviga-
tion. The combination of UB and CT-fluoroscopy is
reported to have a similar diagnostic yield of 78 % in
one study [16]. Data regarding VB combined with UB
are conflicting. In the randomised study by Asano et al,
there was no significant difference of the diagnostic yield
between the VB-assisted group (67 %) and the non-VB-
assisted group (60 %) [17]. However, under the
combined use of EBUS, fluoroscopy, and virtual bron-
choscopic navigation guidance, a recent randomised
study published by Oki et al. could show that the diag-
nostic yield for malignant lesions was significantly higher
with a 3.0-mm ultrathin bronchoscope (74 %) compared
to a 4.0-mm thin bronchoscope (59 %) [18]. The authors
concluded that the combination of UB with navigational
technology and endobronchial ultrasound (EBUS) seems
to combine the best two modalities for evaluating per-
ipheral pulmonary lesions [18]. Interestingly, the diag-
nostic yield of UB was markedly higher in the study by
Oki et al. (74 %) compared to our study (55 %). In con-
trast, the yield of SB was higher in our study (80 %)
compared to 59 % by Oki et al., although a slightly thin-
ner bronchoscope was used in their study [18]. On one
hand, this underlines the conclusion that advanced navi-
gational technologies improve the diagnostic yield of
UB. On the other hand, these differences raise the issue
of the operator’s experience and a possible influence by
the higher TB prevalence in our cohort. An additional
aspect to consider is that VB- or ENB-guided biopsy
techniques increase average costs, which is not feasible in
many parts of the world [19]. Compared to video-assisted
thoracoscopic surgery (VATS) or (18)F-fluoro-deoxyglu-
cose positron emission tomography (FDG-PET), ENB is
more cost-effective to diagnose lung cancer in moderate-
to high-risk patients [20]. Another issue, which should be
considered, is training. The recommended training
requirement for R-EBUS is at least 50 supervised proce-
dures [21]. Issues of costs and training need to be consid-
ered before acquisition and introduction of such
modalities. Some of these diagnostic modalities may not
Table 3 Overall diagnostic yield and sensitivity for the diagnosis of malignancy of ultrathin versus standard size bronchoscopy
Ultrathin bronchoscopy
(n = 20)
Standard size bronchoscopy
(n = 20)
P-value
Overall diagnostic yield 55.0 80.0 0.18
Sensitivity 50.0 (16.0–84.0) 62.5 (24.7–91.0) 0.95
Data in the table are mean values, displayed in % (95 % CI)
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be feasible in less affluent settings. In addition, the benefit
of these highly sophisticated diagnostic tools in an area
with high incidence of TB remains questionable.
The limitations of this study are its small sample size,
since it was originally designed as pilot trial, and that
not all bronchoscopic results were confirmed by surgical
sampling. Interestingly, none of the individuals in whom
observation was considered the appropriate strategy by
the clinical board had a malignant lesion. Furthermore, a
new ultrathin bronchoscope with a larger working chan-
nel has been introduced which most probably leads to
higher yields [13]. All of the UB procedures were done
with a fiberscope, which might have influenced diagnos-
tic yield and could have caused a bias. We did not evalu-
ate the distance of SPL from hilum or presence of
bronchus sign as possible predictors of the diagnostic
yield. Lastly, the bronchoscopies were performed by five
different operators, which may have introduce a certain
bias. However, three of the five operators had a docu-
mented track record from a previous study, and at
least one of them was present in the bronchoscopy suite
for all study related procedures [22].
Conclusions
We conclude that the inspection and sampling with UB
in endoscopically non-visible SPL showed no advantage
over sampling with SB in the evaluation of undiagnosed
SPL in a TB-endemic area, when combined with fluoro-
scopic guidance only. It seems that for the diagnostic
work-up of SPL, tumour visibility is less important than
getting higher volumes of material. Sample material vol-
ume consisting of tumour cells and fluid markers is de-
termined by the diameter of the bronchoscope.
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